PUBLISHER: GlobalData | PRODUCT CODE: 1395947
PUBLISHER: GlobalData | PRODUCT CODE: 1395947
Diabetes Assays Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Diabetes Assays market for the year 2020 and beyond. Diabetes Assays are performed to diagnose individuals at higher risk of developing the disease. Tests that are performed to diagnosis diabetes include glycated haemoglobin (HbA1c) assays, fasting glucose assays, c-peptide assays, and insulin assays. Haemoglobin (HbA1c) assays are the most commonly used for both initial and confirmatory screening of diabetes across all geographical regions. The American Diabetes Association (ADA) recommends HbA1c tests 2 times per year in patients who are meeting treatment goals and additional testing for patients who are not meeting their treatment goals. Screening may be repeated every three years in patients that have normal test results.
Diabetes Assays is segmented into Glycated Hemoglobin Assays (HbA1c), Fasting Glucose Assays, Glycated Hemoglobin (HbA1c) Lab Assay, Glycated Hemoglobin (HbA1c) Point of care (POC) Assay, Insulin Assays, C-Peptide Assays.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Diabetes Assays tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, ALPCO Diagnostics, Bio-Rad Laboratories Inc, DiaSorin SpA, Quidelortho Corp, Sinocare Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Siemens AG, Tosoh Corp, EKF Diagnostics Holdings Plc, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:
The model will enable you to: